Cancer stem cell-targeted chimeric antigen receptor (CAR)-T cell therapy: Challenges and prospects.
10.1016/j.apsb.2020.12.015
- Author:
Javad MASOUMI
1
;
Abdollah JAFARZADEH
2
;
Jalal ABDOLALIZADEH
3
;
Haroon KHAN
4
;
Jeandet PHILIPPE
5
;
Hamed MIRZAEI
6
;
Hamid Reza MIRZAEI
7
Author Information
1. Department of Immunology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan 77181759111, Iran.
2. Department of Immunology, School of Medicine, Kerman University of Medical Sciences, Kerman 7616913555, Iran.
3. Drug Applied Research Center, Tabriz University of Medical Sciences, Tabriz 5165665811, Iran.
4. Department of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan.
5. Research Unit "Induced Resistance and Plant Bioprotection", EA 4707, SFR Condorcet FR CNRS 3417, Faculty of Sciences University of Reims Champagne-Ardenne, BP 1039, 51687, Reims Cedex 2, France.
6. Research Center for Biochemistry and Nutrition in Metabolic Diseases, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan 8713781147, Iran.
7. Department of Medical Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran 1417613151, Iran.
- Publication Type:Review
- Keywords:
Cancer stem cell;
Chimeric antigen receptor T cell;
Clinical trial;
Combination therapy;
Immunotherapy;
Off-tumor toxicity;
Tumor associated antigens;
Tumor immunosuppressive microenvironment
- From:
Acta Pharmaceutica Sinica B
2021;11(7):1721-1739
- CountryChina
- Language:English
-
Abstract:
Cancer stem cells (CSCs) with their self-renewal ability are accepted as cells which initiate tumors. CSCs are regarded as interesting targets for novel anticancer therapeutic agents because of their association with tumor recurrence and resistance to conventional therapies, including radiotherapy and chemotherapy. Chimeric antigen receptor (CAR)-T cells are engineered T cells which express an artificial receptor specific for tumor associated antigens (TAAs) by which they accurately target and kill cancer cells. In recent years, CAR-T cell therapy has shown more efficiency in cancer treatment, particularly regarding blood cancers. The expression of specific markers such as TAAs on CSCs in varied cancer types makes them as potent tools for CAR-T cell therapy. Here we review the CSC markers that have been previously targeted with CAR-T cells, as well as the CSC markers that may be used as possible targets for CAR-T cell therapy in the future. Furthermore, we will detail the most important obstacles against CAR-T cell therapy and suggest solutions.
